System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer

Device Code: 3062

Product Code(s): NIG

Definition: An In Vitro Diagnostic Test For The Quantitative Measurement Of The CA 19-9 Tumor Associated Antigen In Human Serum Or Plasma. The Test Is Intended As An Aid In The Management Of Patients With Confirmed Pancreatic Cancer And Serial Monitoring Of Thei

Device Classification Information

Device Type ID3062
Device NameSystem, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer
Regulation DescriptionTumor-associated Antigen Immunological Test System.
Regulation Medical SpecialtyImmunology
Review PanelImmunology
Premarket Review Office Of In Vitro Diagnostics And Radiological Health (OIR)
Submission Type510(k)
CFR Regulation Number866.6010 [🔎]
FDA Device ClassificationClass 2 Medical Device
Product CodeNIG
GMP ExemptNo
Summary MREligible
Implanted DeviceNo
Life Support DeviceNo
Third Party Review Not Third Party Eligible

Recognized Standards

Total Product Life Cycle

Device Type ID3062
DeviceSystem, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer
Product CodeNIG
FDA Device ClassificationClass 2 Medical Device
Regulation DescriptionTumor-associated Antigen Immunological Test System.
CFR Regulation Number866.6010 [🔎]
Device Problems
High Test Results
148
Adverse Event Without Identified Device Or Use Problem
45
Incorrect Or Inadequate Test Results
37
Low Test Results
26
Non Reproducible Results
3
High Readings
2
No Apparent Adverse Event
1
False Positive Result
1
Device Component Or Accessory
1
Total Device Problems 264
Recalls
Manufacturer Recall Class Date Posted
1
Beckman Coulter Inc.
II Jun-28-2017
2
ORTHO-CLINICAL DIAGNOSTICS
II Aug-11-2014
3
Siemens Healthcare Diagnostics, Inc
II Nov-17-2016
4
Tosoh Bioscience Inc
II Jun-05-2018
TPLC Last Update: 2019-04-02 20:23:16

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.